SANGAMO THERAPEUTICS INC (SGMO)

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Notable Monday Option Activity: MTTR, IBM, SGMO

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

Sangamo stock soars 37% on updates for Fabry disease therapy (NASDAQ:SGMO)

Sangamo Therapeutics (SGMO) stock rallied 37% Monday after the biotech company announced regulatory updates for its gene therapy candidate ST-920 in the treatme

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile

Commit To Buy Sangamo Therapeutics At $0.50, Earn 55.9% Annualized Using Options

A Biotech Slump Is Emptying Labs and Threatening Research on New Drugs

Sangamo Therapeutics Inc.’s cost cuts didn’t hurt just the roughly 162 US workers who lost their jobs this month. It’s also a blow to Jerry Walter, who’s lost five family members and suffered kidney, lung, hearing and heart damage from a rare disease.

RBC Capital downgrades Sangamo as biotech moves to save cash (SGMO)

RBC Capital downgrades Sangamo Therapeutics (SGMO) due to workforce cuts and program pauses, lowering price target to $2 from $6. Read more here.

Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results

Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Sangamo Therapeutics 10% owner Biogen discloses sale of 6M shares (NASDAQ:SGMO)

Sangamo Therapeutics (SGMO) sells 6 million shares for $3 million, according to recent disclosure.

Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit

Notable Wednesday Option Activity: OXY, SGMO, ZM

Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases

Treating rare diseases is a tough but potentially lucrative business. With clinical trials coming due, here are three stocks to buy.